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Abstract The inhibition of the 26S proteasome evokes
endoplasmic reticulum stress, which has been shown to be
implicated in the antitumoral effects of proteasome inhib-
itors. The cellular and molecular effects of the proteasome
inhibitor—bortezomib—on human colon cancer cells are
as yet poorly characterized. Bortezomib selectively induces
apoptosis in some cancer cells. However, the nature of its
selectivity remains unknown. Previously, we demonstrated
that, in contrast to normal fibroblasts, bortezomib treatment
evoked strong effect on apoptosis of breast cancer cells
incubated in hypoxic and normoxic conditions. The study
presented here provides novel information on the cellular
effects of bortezomib in DLD-1 colon cancer cells line. We
observe twofold higher percentage of apoptotic cells
incubated for 48 h with 25 and 50 nmol/l of bortezomib in
hypoxic conditions and four-, fivefold increase in normoxic
conditions in comparison to control cells, incubated with-
out bortezomib. It is of interest that bortezomib evokes
strong effect on necrosis of DLD-1 colon cancer cell line.
We observe the sixfold increase in necrosis of DLD-1 cells
incubated with 25 or 50 nmol/l of bortezomib for 48 h in
hypoxia and fourfold increase in normoxic conditions in
comparison to adequate controls. We suggest that bort-
ezomib may be candidates for further evaluation as che-
motherapeutic agents for human colon cancer.
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Introduction
The proteasome is responsible for the degradation of short-
lived proteins involved in gene expression, cell cycle
progression, DNA repair, apoptosis, and signal transduc-
tion, as well as abnormal and misfolded proteins [1]. Pro-
teasome-mediated protein degradation involves the
covalent attachment of ubiquitin to specific proteins
forming polyubiquitin chains, followed by the recruitment
of these proteins to the proteasome for degradation [2]. The
most common form of the 26S proteasome consists of one
20S core particle structure (700 kDa), which contains the
protease activity, and two 19S regulatory caps (900 kDa
each) [3]. There are three types of proteolytic activity
within the 20S core particle: caspase-like, trypsin-like, and
chymotrypsin-like activities [4].
The inhibition of the proteasome results in many toxic
effects, including increased levels of ROS and the accu-
mulation of unfolded and damaged proteins [5–7]. In
response to proteasome inhibition, the cell induces specific
protective mechanisms, including the unfolded protein
response [5], autophagy [8, 9], and, if the damage is severe,
apoptosis [5, 10, 11].
Bortezomib (PS-341; VelcadeTM), a highly selective and
reversible inhibitor of the 26S proteasome approved for
clinical use against multiple myeloma, is in clinical trials as
a single agent or in combination with chemotherapeutics
against other solid tumor malignancies [12]. The chemical
name for bortezomib is [(1R)-3-methyl-1-({(2S)-3-phenyl-
2-[(pyrazin-2-ylcarbonyl)amino]pro-panoyl}amino)-butyl]
boronic acid. The mechanisms involved in its anti-cancer
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activity are still being elucidated, but evidence suggests
that it inhibits proteasome degradation of IjB, an inhibitor
of nuclear factor-jB (NF-jB) in the cancer cell [13–16].
Recently, bortezomib was shown to induce ER stress and
ER-dependent apoptosis by blocking the ERAD system
thereby promoting the accumulation of misfolded proteins
in the ER that induce proteotoxicity and cell death [17, 18].
Rapidly proliferating cancer cells require increased ER
activity to facilitate the folding, assembly, and transport of
membrane and secretory proteins, and are thereby subjected
to ER stress. Due to inadequate vascularization and rapid
growth, tumor cells encounter growth-limiting conditions
such as hypoxia and nutrient deprivation [19]. Tumor
hypoxia is an important feature of the tumor microenvi-
ronment which is the factor promoting cancer progression,
decreased response to therapy, and a poor patient survival
[20]. Hypoxic tumor cells activate hypoxia inducible factor
(HIF)-dependent and HIF-independent survival mecha-
nisms that promote cancer progression [21, 22].
ER stress occurs when the protein load exceeds the ER
capacity to fold or degrade them and is manifested by the
accumulation of malfolded proteins in the endoplasmic
reticulum. ER stress triggers a quality control mechanism,
the unfolded protein response (UPR), which aims at
restoring ER homeostasis by activating a cascade of sig-
naling molecules to transiently arrest protein translation, to
induce ER molecular chaperones and enzymes that
enhance the protein folding capacity, and to initiate a
process to export and degrade the misfolded ER proteins
[23, 24].
One arm of the unfolded protein response is PERK-
eIF2a-ATF4 pathway. In addition to PERK, UPR signaling
is mediated by two other ER transmembrane proteins:
IRE1 and ATF6. Upon ER stress, active IRE1 processes
XBP-1 mRNA, removing a 26-nucleotide intron to gener-
ate a spliced XBP-1 mRNA encoding the functional XBP-1
transcription factor [25, 26]. Together, these pathways
coordinately upregulate transcription of UPR target genes,
such as the ER chaperone BiP/GRP78 and proteins
involved in ER-associated degradation (ERAD), which aid
in restoring ER homeostasis. The ERAD system shuttles
misfolded proteins from the ER lumen to the cytosol where
they become ubiquitinated and degraded by the 26S pro-
teasome [27]. However, IRE1 and another UPR target,
CHOP, are also involved in ER stress-induced apoptosis
[28]. Thus the UPR, while activated as a pro-survival
response under moderate or intermittent ER stress, can also
lead to cell death under conditions of acute or chronic
stress [24].
Apoptosis plays a major role in the control of cancer
development. In fact, cells encounter multiple apoptotic
stimuli during cancer progression, including hypoxia or
nutrient deprivation. The function of this process is to
eliminate unwanted or injured cells with characteristic
cellular and biochemical hallmarks. Accordingly it has
been suggested that the well-documented anti-apoptotic
potential of chaperones may play a critical role in the
suppression of apoptosis in cancer cells [29, 30].
While one attractive approach to target the UPR in
tumors is to develop inhibitors against its effectors (against
PERK or IRE1), we postulated that another approach could
take advantage of its pro-death activity under extreme or
prolonged stress. We decided to study the effect of bort-
ezomib and ER stress, evoked by hypoxia, on apoptosis
and necrosis of colon cancer cell line—DLD-1.
Materials and methods
Reagents
Dulbecco’s modified Eagle’s medium (DMEM), containing
glucose at 4.5 mg/ml (25 mM) with Glutamax, penicillin,
streptomycin, trypsin–EDTA were provided by Invitrogen
(San Diego, USA), passive lysis buffer by Promega
(Madison, USA), FBS Gold by Gibco (San Diego, USA),
bortezomib by Selleckchem (Houston, USA), BCA Protein
Assay Kit by Thermo Scientific (Rockford, USA), PE
Annexin V Apoptosis Detection Kit I by BD Pharmin-
genTM (CA, USA), Senescence Detection Kit by bioVision
(CA, USA), Sigma-Fast BCIP/NBT reagent by Sigma (St
Louis, MO, USA), Precision Plus Protein Standards dual
color by Bio-Rad (Hercules, USA), monoclonal (mouse)
anti-human ORP150 antibody by IBL (Gunma, Japan),
monoclonal (mouse) anti-HIF-1a antibody by BD Biosci-
ences (CA, USA), polyclonal (rabbit) NF-jB2 p100/p52
antibody by Cell Signaling Technology (Boston, USA),
alkaline phosphatase-labeled anti-mouse immunoglobulin
G by Rockland (PA, USA), and anti-rabbit IgG HRP-linked
antibody by Cell Signaling Technology (Boston, USA).
Cell cultures
Human colon cancer cell line DLD-1 was obtained from
American Type Culture Collection (ATCC). The cells were
maintained in high-glucose DMEM supplemented with
10 % heat-inactivated fetal bovine serum GOLD (FBS
GOLD), 2 mM L-glutamine, penicillin (100 U/ml), and
streptomycin (100 lg/ml). DLD-1 cells were cultured in
Falcon flasks (BD) in a 5 % CO2 incubator (Galaxy S?; New
Brunswick) at 37 C. Subconfluent cultures were detached
with 0.05 % trypsin, 0.02 % EDTA in calcium-free phos-
phate-buffered saline (PBS), and counted in a Scepter cell
counter (Millipore), and then 5 9 105 cells were seeded in
six-well plates in 2 ml of growth medium for determination
of protein concentration. In these conditions, they reached
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70–80 % confluence. After incubation, the culture media
were removed; the cells were washed with PBS and sub-
mitted to the action of lysis buffer for determination of
protein concentration. It allowed the detachment of the cells
and extracellular matrix from the bottom of culture vessels
and their suspension in the buffer. The cells incubated on
Petri dishes were exposed to hypoxic conditions.
Cell viability
Cell viability was measured according to the method of
Carmichael [31] using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). Briefly, cells were
seeded in 24-well plate at a density of 100,000 per well.
Confluent cells, cultured for 12, 24, and 48 h in normoxic
conditions with different concentrations of bortezomib, were
washed three times with PBS and then incubated with 1 ml of
MTT solution (0.25 mg/ml in PBS) for 4 h at 37o C in 5 %
CO2 in an incubator. The medium was removed and 1 ml of
0.1 mol/l HCl in absolute isopropanol was added. Absor-
bance of converted dye in living cells was measured at the
wavelength of 570 nm. The viability of DLD-1 cells cul-
tured in hypoxic conditions was calculated as the percentage
of control cells incubated in normoxia. All the experiments
were done in duplicate in at least three cultures.
Induction of hypoxia in cell cultures
The cells (5 9 105 in 2 ml of medium) were seeded in six-
well plates and incubated until they achieved confluence.
The high-glucose DMEM was removed and replaced with
2 ml of the same fresh medium with 25 or 50 nmol/l of
bortezomib. Control cell cultures were kept in normoxic
conditions whereas the tested cells were incubated in
hypoxic conditions. Hypoxia was evoked by 12, 24, and
48 h incubation of cells in atmosphere containing a
reduced to 1 % oxygen in hypoxia chamber (Galaxy 170R;
New Brunswick an Eppendorf company). After incubation,
the culture media were removed; the cell layers were
washed with PBS and submitted to the action of lysis
buffer for the determination of ORP150/GRP170, HIF-1a,
NF-jB2 p100/p52 expression and protein assay. It allowed
the separation of cells and extracellular matrix from the
bottom of culture vessels and their suspension in the
buffer. The cells incubated on six-well plates were
detached with trypsin and analyzed by flow cytometry
method.
Detection of apoptosis
Cells were incubated in the high-glucose DMEM in hyp-
oxic and normoxic conditions with different concentrations
of bortezomib. The incubation was continued for 12, 24,
and 48 h. Apoptosis was evaluated by flow cytometry on
FACSCanto II cytometer (Becton Dickinson). The cells
were trypsinized, resuspended in DMEM, and then in
binding buffer. Cells were stained with FITC Annexin V
and PI for 15 min at room temperature in the dark fol-
lowing the manufacturer’s instructions (FITC Annexin V
apoptosis detection Kit I). Data were analyzed with
FACSDiva software and dead cells were excluded based on
forward- and side-scatter parameters.
Sodium dodecyl sulfate/Polyacrylamide gel
electrophoresis (SDS/PAGE)
Cells were washed with cold PBS and solubilized in 100 ll
of passive lysis buffer per well. The lysates were centri-
fuged for 10 min at 12,0009g at 4 C. Samples of lysates
containing 20 lg of protein were subjected to SDS–PAGE,
as described by Laemmli [32]. The Bio-Rad Precision Plus
Protein Standards dual color were used. The electropho-
resis was run for 40–45 min. In each experiment, 7.5 %
polyacrylamide gel and constant current (25 mA) were
used.
Immunoblotting
The proteins were transferred to nitrocellulose membranes
and then pre-treated for 2 h with Tris-buffered saline
(TBS) containing 0.05 % Tween 20 (TBS-T) and 5 % non-
fat dry milk, at room temperature. Membranes were probed
for 16 h with a mixture containing monoclonal (mouse)
anti-human ORP150 antibody (1:100) or monoclonal
(mouse) anti-human HIF-1a (1:500) or polyclonal (rabbit)
NF-jB2 p100/p52 antibody (1:1,000) in 5 % dried milk in
TBS-T, at 4 C. Then the alkaline phosphatase-conjugated
antibody against mouse IgG at 1:2,500 dilution or anti-
rabbit IgG HRP-linked (1:1,000) was added for 1 h in
TBS-T with slow shaking. The nitrocellulose was washed
with TBS-T (five times for 5 min) and exposed to Sigma-
Fast BCIP/NBT reagent.
Protein assay
Protein concentration in cell lysates was determined by the
method of Smith et al. [33] using BCA Protein Assay Kit
(Thermo Scientific, USA). Bovine serum albumin was used
as a standard.
Statistical analysis
Mean values from three independent experiments ± stan-
dard deviations (SD) were calculated. Statistical analysis
was performed using Student’s t test.
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Results
The effect of bortezomib on viability of DLD-1 cell line
The antiproliferative effect of bortezomib was assessed by
MTT method in DLD-1 cells cultured with increasing
concentrations of bortezomib for periods of 12, 24, or 48 h.
Figure 1 shows that bortezomib, in the concentration from
3 to 1,000 nmol/l, caused a time-dependent and dose-
dependent strong reduction in cell viability of the colon
cancer DLD-1 cells. An evident inhibition in cell viability
was observed as early as after 24 h. In cells treated with
higher concentrations of bortezomib, the effect on cell
viability was markedly more pronounced (Fig. 1). These
results show that bortezomib exhibits a time-dependent and
dose-dependent evident inhibition in cell viability of colon
cancer DLD-1 cells. Two concentrations of bortezomib (25
and 50 nmol/l) were chosen for further study. Both were up
to the value of the half maximal inhibitory concentration
(IC50) for bortezomib.
Detection of HIF-1a in DLD-1 cells submitted
to hypoxia
We also characterized the expression of HIF-1a, a bio-
chemical marker of hypoxia. Figure 2 shows that DLD-
1cells grown in normoxic conditions with or without
bortezomib (for 12 h—lanes 1–3; for 24 h—lanes 7–9; for
48 h—lanes 13–15) demonstrate a weak expression of
HIF-1a. In contrast, those cells incubated in hypoxic con-
ditions demonstrated an intense expression of HIF-1a after
12 h of incubation with or without bortezomib (Fig. 2,
lanes 4–6). After 24 h without bortezomib, we observe a
weak expression of HIF-1a (Fig. 2, lane 10) and strong
expression with bortezomib, especially with 50 nmol/l
concentration (Fig. 2, lane 12). In contrast to 12 and 24 h,
after 48 h incubation of DLD-1 cells in hypoxic conditions
without bortezomib, we observe an intense expression of
HIF-1a (Fig. 2, lane 16). It is worthy of note that incuba-
tion of these cells in hypoxic conditions with bortezomib
did not demonstrate the HIF-1a expression with 25 and
50 nmol/l of bortezomib (Fig. 2, lanes 17, 18). Addition-
ally, the expression of HIF-1a after 12 h in hypoxic con-
ditions with bortezomib (lanes 5, 6) was higher in
comparison to the same cells incubated for 24 (lanes 11,
12) or 48 h (lanes 17, 18).
The effect of bortezomib on apoptosis of DLD-1 cells
submitted to hypoxia
Next, we investigated whether bortezomib toxicity was due
to the induction of apoptosis. Figure 3 shows the per cent
of apoptotic DLD-1 cells incubated for 12, 24, or 48 h in
normoxic and hypoxic conditions with 25 or 50 nmol/l of
bortezomib. In the cells incubated for 12, 24, and 48 h in
hypoxic and normoxic conditions with bortezomib, we
observed a time-dependent and dose-dependent increase in
apoptosis of DLD-1 cells (Fig. 3). The per cent of apop-
totic cells after 12, 24, and 48 h of incubation was signif-
icantly higher for 50 nmol/l of bortezomib in comparison
to control cells. We observe twofold higher percentage of
apoptotic cells incubated for 48 h with 25 and 50 nmol/l of
bortezomib in hypoxic conditions and 3, 4-fold higher in
normoxic conditions in comparison to adequate control
cells, incubated without bortezomib. The per cent of
apoptotic cells in the colon cancer cells cultured in hypoxia
was higher in comparison to the same cells incubated in
normoxia, notwithstanding the incubation time and con-
centration of bortezomib (Fig. 3).
The effect of bortezomib on necrosis of DLD-1 cells
submitted to hypoxia
Next, we investigated whether bortezomib toxicity was due
to the induction of necrosis. Figure 4 shows the per cent of
necrotic DLD-1 cells incubated for 12, 24 or 48 h in
normoxic and hypoxic conditions with 25 or 50 nmol/l of
bortezomib. In the cells incubated for 12, 24, and 48 h in
hypoxic and normoxic conditions with bortezomib, we
Fig. 1 The viability of DLD-1 cells treated with different concen-
trations of bortezomib for 12, 24, and 48 h. Mean values from three
independent experiments ± SD are presented. Significant alterations
are expressed relative to controls and marked with asterisks.
Statistical significance was considered if * p \ 0.05
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observed a time-dependent increase in necrosis of DLD-1
cells (Fig. 4). The per cent of necrotic cells after 12 h for
50 nmol/l and after 24 and 48 h of incubation for both
concentrations of bortezomib was significantly higher in
comparison to adequate control cells. We observe the
fourfold increase in necrosis of DLD-1 cells incubated with
25 or 50 nmol/l of bortezomib for 48 h in normoxia and
sixfold increase in hypoxic conditions in comparison to
adequate control. After 24 and 48 h, the per cent of
necrotic cells in the colon cancer cells cultured in hypoxia
Fig. 2 Western blot analysis of HIF-1a synthesized by DLD-1 cells
incubated in normoxic and hypoxic conditions for 12, 24 and 48 h.
Samples containing 20 lg of protein were submitted to
electrophoresis and immunoblotting. A representative Western blot
is presented. The molecular mass (MM) of the precision plus protein
standards are indicated on the left side of the lanes
Fig. 3 The effect of bortezomib on apoptosis of DLD-1cells
incubated in normoxic and hypoxic conditions for 12, 24 and 48 h.
Mean values from three independent experiments ± SD are pre-
sented. Significant alterations are expressed relative to controls and
marked with asterisks. Statistical significance was considered if
*p \ 0.05
Fig. 4 The effect of bortezomib on necrosis of DLD-1 cells
incubated in normoxic and hypoxic conditions for 12, 24 and 48 h.
Mean values from three independent experiments ± SD are pre-
sented. Significant alterations are expressed relative to controls and
marked with asterisks. Statistical significance was considered if
* p \ 0.05
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was twofold higher in comparison to the same cells incu-
bated in normoxia, notwithstanding the concentration of
bortezomib (Fig. 4).
The effect of bortezomib on the expression of ORP150
Overexpression of Hsp70 chaperones (ORP150 belongs to
this family) may protect cancer cells against entering the
apoptotic pathway. Figure 5 shows the expression of
GRP170, glycosylated form of ORP150, in DLD-1 incu-
bated in normoxic and hypoxic conditions with 25 and
50 nmol/l of bortezomib.
The expression of GRP170 in DLD-1 was observed in
cultures incubated in normoxic and hypoxic conditions for
12 and 24 h, notwithstanding the concentration of bort-
ezomib (Fig. 5; lanes 1–12). We did not observe the
induction of ORP150 expression in hypoxic conditions in
DLD-1 incubated for 12, 24 and 48 h, notwithstanding the
concentration of bortezomib (Fig. 5; lanes: 1–18). It is of
interest that DLD-1 cells incubated for 48 h in hypoxic
conditions with 25 and 50 nmol/l of bortezomib did not
express both GRP170 and ORP150 (Fig. 5; lanes 17 and
18), while without bortezomib, we observed a strong
expression of GRP170 (Fig. 5; lane 16).
The effect of bortezomib on the expression of NF-jB
in DLD-1 cells submitted to hypoxia
We also characterized the expression of NF-jB2, the factor
involved in suppression of apoptosis. The expression of
NF-jB in DLD-1 was observed in cultures incubated in
normoxic conditions for 12, 24 and 48 h, notwithstanding
the concentration of bortezomib (Fig. 6; lanes 1–3, lanes
7–9, lanes 13–15). The induction of NF-jB expression was
observed in hypoxic conditions in DLD-1 incubated for 12
and 24 h, notwithstanding the concentration of bortezomib
(Fig. 6; lanes: 4–6, 10–12). It is of interest that DLD-1 cells
incubated for 48 h in hypoxic conditions with 25 or
50 nmol/l of bortezomib did not express NF-jB (Fig. 6;
lanes 17 and 18).
Discussion
We have investigated the effect of the proteasome inhibi-
tor—bortezomib with the physiologic stress of hypoxia on
tumor cells. The inhibition of the 26S proteasome evokes
endoplasmic reticulum stress, which has been shown to be
implicated in the antitumoral effects of proteasome inhib-
itors. The cellular and molecular effects of the proteasome
inhibitor—bortezomib—on human colon cancer cells are
as yet poorly characterized. Bortezomib selectively induces
apoptosis in some cancer cells. However, the nature of its
selectivity remains unknown. Previously, we demonstrated
that in contrast to normal fibroblasts, bortezomib treatment
evoked strong effect on apoptosis of breast cancer cells
incubated in hypoxic and normoxic conditions [34]. The
study presented here provides novel information on the
cellular effects of bortezomib in colon cancer cells line
DLD-1. We observe twofold higher percentage of apop-
totic cells incubated for 48 h with 25 and 50 nmol/l of
bortezomib in hypoxic conditions and 4-, 5-fold increase in
normoxic conditions in comparison to control cells incu-
bated without bortezomib.
Another form of cell death, necrosis, may be triggered
by metabolic stress under conditions of defective apoptosis
or prolonged autophagy. It is of interest that bortezomib
evokes strong effect on necrosis of DLD-1 colon cancer
cell line both in hypoxic and normoxic conditions. We
observe the sixfold increase in necrosis of DLD-1 cells
incubated with 25 or 50 nmol/l of bortezomib for 48 h in
hypoxia and fourfold increase in normoxic conditions in
comparison to adequate controls. Our findings suggest that
it may be possible to ‘‘push’’ hypoxic tumor cells into
necrosis by overactivating the ER stress-dependent
mechanisms.
Fig. 5 Western blot analysis of ORP150/GRP170 synthesized in
DLD-1 cells incubated with 25 and 50 nmol/l of bortezomib in
normoxic and hypoxic conditions for 12, 24 and 48 h. Samples
containing 20 lg of protein were submitted to electrophoresis and
immunoblotting. A representative Western blot is presented. The
molecular mass (MM) of the precision plus protein standards are
indicated on the left side of the lanes
170 Mol Cell Biochem (2015) 398:165–173
123
The precise mechanism of hypoxia-induced, ER-
dependent cell death is still unknown. In agreement with
other reports, one potential player may be the pro-apoptotic
protein CHOP, induced by bortezomib, hypoxia and com-
bined treatment [17, 18].
The maintenance of protein homeostasis in cell requires
the activities of chaperones and the ubiquitin–proteasome
system, which together serve to inactivate and degrade
misfolded proteins. When proteins are not folded properly,
they are directed to 26S proteasomal degradation. If mis-
folded or unfolded proteins are not degraded by the pro-
teasome, they form aggregates and lead to the ER stress.
The ER stress triggers UPR to reduce the accumulation of
unfolded proteins and restore the ER function. When pro-
tein aggregation or ER stress persists, the UPR signaling
switches from the pro-survival to pro-apoptotic. Conse-
quently, the 26S proteasome complex also plays an
important role in regulating the ER stress and cell survival.
Therefore, inhibition of the proteasomal function in cancer
cells would promote apoptosis and have an anti-tumor
function [9]. In fact, the inhibition of the proteolytic
activity of the 26S proteasome has been shown to induce
pro-apoptotic ER stress in multiple myeloma [18], pan-
creatic [17], head and neck cancer [11], and non-small cell
lung carcinoma [35].
Proteasomal activity is essential for eliminating excess
proteins, and by counteracting protein production, it
establishes steady protein levels [36]. The ubiquitin pro-
teasome pathway represents the major pathway for intra-
cellular protein degradation. The 26S proteasome is
responsible for the degradation of approximately 80 % of
cellular proteins, including misfolded and mutated proteins
as well as those involved in the regulation of development,
differentiation, cell proliferation, signal transduction,
apoptosis, and antigen presentation [13].
Prolonged proteasome inhibition induces stress respon-
ses that initiate apoptosis via intrinsic pathway [36]. This is
exploited clinically in the treatment of multiple myeloma
with the proteasome inhibitor bortezomib. Inhibition of
proteasome activity by bortezomib is associated with an
accumulation and transcriptional induction of BH3-only
proteins such as PUMA, BIM, NOXA, or BIK. BH3-only
proteins antagonize anti-apoptotic BCL-2 family members
such as BCL-2, BCL-xL, or Mcl-1 and can activate the pro-
apoptotic members BAX and BAK [37]. Activated BAX
and BAK form pores in the outer mitochondrial membrane,
resulting in cytochrome c and Smac/Diablo release from
the intermembrane space into the cytosol. This results in
caspase-9 activation, inhibition of IAP (inhibitor of apop-
tosis proteins), and subsequent apoptosis execution by
effector caspases [37]. Induction of NOXA has been
reported to be a key mechanism in bortezomib-mediated
apoptosis which is independent of P53 status but dependent
on c-Myc [38–40]. Bortezomib-mediated apoptosis is
accompanied by the induction of c-Jun-NH2 terminal
kinase, generation of reactive oxygen species, release of
cytochrome c, second mitochondria-derived activator of
caspases, and apoptosis-inducing factor, and activation of
the intrinsic caspase-9 pathway and extrinsic caspase-8
pathway [13].
In agreement with the cytoprotective role of molecular
chaperones it has been shown, that they can prevent
stress-induced apoptosis [29, 30]. Overexpression of
Hsp70 chaperones (ORP150 belongs to this family) pre-
vents cytochrome c release from mitochondria, blocks
apoptosome formation by binding to the apoptotic prote-
ase-activating factor (Apaf-1), inhibits the release of
apoptosis-inducing factor (AIF) from mitochondria, and
prevents the loss of mitochondrial transmembrane poten-
tial. The AIF released from mitochondria binds to Hsp70
and this interaction makes impossible the nuclear import
of AIF [30]. It is of interest that DLD-1 cells incubated
for 48 h in hypoxic conditions with 25 and 50 nmol/l of
bortezomib did not express both GRP170 and ORP150,
while without bortezomib we observed strong expression
of GRP170.
Fig. 6 Western blot analysis of NF-jB synthesized in DLD-1 cells
incubated with 25 and 50 nmol/l of bortezomib in normoxic and
hypoxic conditions for 12, 24 and 48 h. Samples containing 20 lg of
protein were submitted to electrophoresis and immunoblotting. A
representative Western blot is presented. The molecular mass (MM)
of the precision plus protein standards are indicated on the left side of
the lanes
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The transcription factor NF-jB is believed to play a
vital role in the action of bortezomib as it is involved in the
suppression of apoptosis and induction of cancer cell pro-
liferation, invasion, metastasis, tumorigenesis, and angio-
genesis [41]. NF-jB2 is heterodimer of p52 and p65. The
26S proteasome is involved in generating p52 from the
precursor protein p100. Then p52 binds to p65 and
becomes the active dimer of NF-jB2. In the cytosol,
inhibitor of NF-jB (IjB) binds to NF-jB and inhibits the
translocation of NF-jB to the nucleus for gene activation
[41]. NF-jB is activated by proteasomal degradation of
IjB. It is of interest that DLD-1 cells incubated for 48 h in
hypoxic conditions with 25 and 50 nmol/l of bortezomib
did not express NF-jB in contrast to the same cells incu-
bated in normoxic conditions.
Proteasome inhibitor bortezomib promotes cell death in
colon cancer cell line DLD-1 both through apoptosis and
necrosis. We suggest that in the mechanism of DLD-1, cell
death is involved in the suppression of chaperone GRP170
and inhibition of transcription factor NF-jB synthesis.
Chaperone induction in cancer cells can lead to cancer
progression and may be a major cause of chemotherapeu-
tics resistance. It is one of the mechanisms protecting
cancer cells against entering the apoptotic pathway. Hence,
chaperone inhibition may be a promising tool to decrease
cytoprotection and to initiate apoptosis of cancer cells [42].
In conclusion, bortezomib represents compounds, which
are able to induce apoptosis and necrosis in human cancer
cells in low dose. We suggest that bortezomib may be
candidates for further evaluation as chemotherapeutic
agents for human colon cancer.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
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